New drug option for Hard-to-Treat cancers with FGFR3 mutations

NCT ID NCT07675057

AVAILABLE Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, and cannot join an ongoing vepugratinib clinical trial. The goal is to offer a potential treatment option when no others are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vepugratinib
What this could lead to: If it works, this could provide a treatment option for people with certain cancers that have not responded to other therapies.
What could go wrong: This is an expanded access program, not a formal trial, so effectiveness and safety are not fully established. It may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, TRANSITIONAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis transitional cell carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, TRANSITIONAL CELL NEOPLASM METASTASIS URINARY BLADDER NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.